[go: up one dir, main page]

AR019438A1 - COMPOSITE DERIVED FROM PIPERAZINA, USES OF THE SAME AND METHODS FOR ITS MANUFACTURE - Google Patents

COMPOSITE DERIVED FROM PIPERAZINA, USES OF THE SAME AND METHODS FOR ITS MANUFACTURE

Info

Publication number
AR019438A1
AR019438A1 ARP990103573A ARP990103573A AR019438A1 AR 019438 A1 AR019438 A1 AR 019438A1 AR P990103573 A ARP990103573 A AR P990103573A AR P990103573 A ARP990103573 A AR P990103573A AR 019438 A1 AR019438 A1 AR 019438A1
Authority
AR
Argentina
Prior art keywords
substituted
och3
alkanes
piperazina
manufacture
Prior art date
Application number
ARP990103573A
Other languages
Spanish (es)
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/120,265 external-priority patent/US6083950A/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AR019438A1 publication Critical patent/AR019438A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4042,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4042,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se ha encontrado que los nuevos derivados de piperazina substituidos en un nitrogeno por un sistema aromático y en otro nitrogeno por (2,5-dioxopirrolidin-1-il)alcanos o (2,6-dioxopiperidin-1-il)alcanos, exhiben una actividad alfa1A-adregérgica selectiva. Los compuestos son utiles para el tratamiento de estadosde enfermedad, tales como la enfermedad vascular periférica, la insuficiencia cardíaca congestiva, la hipertension y, especialmente, para la hipertrofiaprostática benigna. Particularmente,el compuesto derivado de piperazina, tiene la estructura de la formula (1) sus sales farmacéuticamente aceptables,ésteres, enantiomeros, diastereomeros, N-oxidos, amidas, prodrogas o metabolitos donde Y es O o S; Q, X, Z y Z son independientemente CH o N; m = 0-3; n =0-4; R1 y R2 se seleccionan independientemente entre H, F, Cl, Br, OCH3, OC2H5, OCH2CF3, SCF3, CH3, C2H5, CF3, isopropiloxi y ciclopropilo; R3 es HR6, OH uOR6; R6 es una cadena alquilo C1-6 sustituida o no sustituida; y R4 y R5 sonH, alquilo C1-3 fenil sustituido o no sustituido, o un anillo ciclíco de 5miembros con la excepcion de que R1 es H, R2 es H, Cl o CF3, R3, R4 y R5 = H, Y = O y Q = CH cuando m = 0 y n = 1; y también excepto que R1 es H, R2 esOCH3, R3, R4 y R5 = H, Y= O, Q = CH cuando m = 0 y n = 2.It has been found that the new piperazine derivatives substituted in one nitrogen by an aromatic system and in another nitrogen by (2,5-dioxopyrrolidin-1-yl) alkanes or (2,6-dioxopiperidin-1-yl) alkanes, exhibit a selective alpha1A-adrenergic activity. The compounds are useful for the treatment of disease states, such as peripheral vascular disease, congestive heart failure, hypertension and, especially, for benign hypertrophyprostatics. Particularly, the piperazine-derived compound has the structure of the formula (1) its pharmaceutically acceptable salts, esters, enantiomers, diastereomers, N-oxides, amides, prodrugs or metabolites where Y is O or S; Q, X, Z and Z are independently CH or N; m = 0-3; n = 0-4; R1 and R2 are independently selected from H, F, Cl, Br, OCH3, OC2H5, OCH2CF3, SCF3, CH3, C2H5, CF3, isopropyloxy and cyclopropyl; R3 is HR6, OH uOR6; R6 is a substituted or unsubstituted C1-6 alkyl chain; and R4 and R5 are H, C1-3 alkyl substituted or unsubstituted phenyl, or a 5-member cyclic ring with the exception that R1 is H, R2 is H, Cl or CF3, R3, R4 and R5 = H, Y = O and Q = CH when m = 0 and n = 1; and also except that R1 is H, R2 is OCH3, R3, R4 and R5 = H, Y = O, Q = CH when m = 0 and n = 2.

ARP990103573A 1998-07-21 1999-07-21 COMPOSITE DERIVED FROM PIPERAZINA, USES OF THE SAME AND METHODS FOR ITS MANUFACTURE AR019438A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/120,265 US6083950A (en) 1997-11-13 1998-07-21 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers

Publications (1)

Publication Number Publication Date
AR019438A1 true AR019438A1 (en) 2002-02-20

Family

ID=22389214

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103573A AR019438A1 (en) 1998-07-21 1999-07-21 COMPOSITE DERIVED FROM PIPERAZINA, USES OF THE SAME AND METHODS FOR ITS MANUFACTURE

Country Status (10)

Country Link
CN (1) CN1168714C (en)
AR (1) AR019438A1 (en)
AU (1) AU1979799A (en)
CO (1) CO5241280A1 (en)
CZ (1) CZ2001235A3 (en)
ID (1) ID28198A (en)
MY (1) MY120255A (en)
RU (1) RU2221794C2 (en)
WO (1) WO2000005206A1 (en)
ZA (1) ZA200100440B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1787995A (en) * 2002-04-08 2006-06-14 兰贝克赛实验室有限公司 Alpha, omega-dicarboximide derivatives as useful uro-selective alpha1alpha adrenoceptor blockers
US7053355B2 (en) 2003-03-18 2006-05-30 Brion Technologies, Inc. System and method for lithography process monitoring and control
AU2003278403A1 (en) * 2003-10-15 2005-05-05 Ranbaxy Laboratories Limited 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist
WO2005113498A1 (en) * 2004-05-19 2005-12-01 Ranbaxy Laboratories Limited Adrenergic receptor antagonists
WO2005118591A1 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Condensed piperidine compounds acting as adrenergic receptor antagonists useful in the treatment of prostatic hyperplasia and lower urinary symptoms
WO2006018815A1 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Piperazine derivatives as adrenergic receptor antagonists
WO2006051374A2 (en) * 2004-11-11 2006-05-18 Ranbaxy Laboratories Limited Arylpiperazines useful as adrenergic receptor antagonists
CN103864761B (en) * 2014-03-12 2016-01-20 天津药物研究院有限公司 A kind of piperazine derivative containing pyridine and its production and use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788280A (en) * 1971-09-04 1973-02-28 Pfizer NEWS 1- (3-TRIFLUORO-METHYL-PHENYL) -4 - ((CYCLIC AMIDO) - ALKYL) PIPERAZINES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
DE2727469A1 (en) * 1977-06-18 1978-12-21 Hoechst Ag NEW HEXAHYDROPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPS57197265A (en) * 1981-05-29 1982-12-03 Eisai Co Ltd Carboxylic acid imide derivative, its preparation and medicament containing the same
US4452798A (en) * 1982-06-22 1984-06-05 Warner-Lambert Company 1-Substituted phenyl-4-alkyl hydantoin piperazine compounds as antihypertensive agents
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
FR2672052B1 (en) * 1991-01-28 1995-05-24 Esteve Labor Dr DERIVATIVES OF ARYL (OR HETEROARYL) -PIPERAZINYL-ALKYL-AZOLES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS.
ES2094690B1 (en) * 1994-11-22 1997-08-01 Univ Madrid Complutense NEW DERIVATIVES OF IMIDA-PIPERAZINES.
PT748800E (en) * 1995-06-09 2001-10-30 Hoffmann La Roche DERIVATIVES OF PYRIMIDINADIONA PYRIMIDINATRIONA TRIAZINADIONA AS ANTAGONISTS OF THE ALPHA-1-ADRENERGIC RECEPTOR

Also Published As

Publication number Publication date
ZA200100440B (en) 2002-10-04
RU2221794C2 (en) 2004-01-20
CN1318052A (en) 2001-10-17
CN1168714C (en) 2004-09-29
CO5241280A1 (en) 2003-01-31
WO2000005206A8 (en) 2000-03-16
MY120255A (en) 2005-09-30
AU1979799A (en) 2000-02-14
CZ2001235A3 (en) 2001-08-15
ID28198A (en) 2001-05-10
WO2000005206A1 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
PE20020504A1 (en) APOPTOSIS-PROMOTING N-ACILSULFONAMIDES
UY27357A1 (en) NEW ANTIDIABETIC AGENTS.
GB2303851A (en) Pharmaceutical diketopiperazine compounds
PE10290A1 (en) BENZOTRIAZOL DERIVATIVES PREPARATION PROCEDURE
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
DE68906183D1 (en) 2'-DESOXY-5-FLUORURIDINE DERIVATIVES.
CY1110355T1 (en) Activator of subunit multiplexer subunit activator D
PE20011314A1 (en) DERIVATIVES OF N- (4-CARBAMIMIDOYL-PHENYL) -GLYCIN AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS Xa IXa AND THROMBIN
CU23413B7 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
ATE362931T1 (en) 8-AZABICYCLO(3.2.1)OCT-2EN DERIVATIVES, THEIR PRODUCTION AND APPLICATION
AR043485A1 (en) DERIVATIVES OF 8'-PIRIDINIL-DIHIDROSPIRO- [CICLOALQUIL] -PIRIMIDO [1,2A] PIRIMIDIN-6-ONA AND 8´-PIRIMIDINIL-DIHIDROSPIRO- [CICLOALQUIL] -PIRIMIDO [1,2A] PIRIMIDIN-6-ONA SUBSTITUTED
MX9602979A (en) Indole derivatives as 5-ht1 agonists.
AR019438A1 (en) COMPOSITE DERIVED FROM PIPERAZINA, USES OF THE SAME AND METHODS FOR ITS MANUFACTURE
PT1216245E (en) PHARMACEUTICALLY ACTIVE SULFONYL HYDROXIDE DERIVATIVES
ATE127117T1 (en) 1-ARYL-1-HYDROXY-1-SUBSTITUTED-3-(4-SUBSTITUTED-1-PIPERAZINYL)-2-PROPANONES AND THEIR USE IN THE TREATMENT OF BLADDER DISORDERS OF NEUROLOGICAL ORIGIN.
AR036602A1 (en) MUSCARINIC AGONISTS
PE20021018A1 (en) DERIVATIVES OF ß - CARBOLINE
CO5540385A2 (en) OXAZOL ARILPROPIONIC ACID CHIRAL DERIVATIVES, THEIR SYNTHESIS METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR021900A1 (en) DERIVED FROM THE CHROMAN, ITS SALTS AND ENANTIOMERS, A PROCEDURE FOR ITS PREPARATION AND THE USE OF THE SAME AS INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF MEDICINES.
NO20050612L (en) Pyrrolidine derivatives as oxytocin antagonists
AR040123A1 (en) THIOPHEN, ANTIHELMINTIC AND INSECTICIDE COMPOUNDS
ES2068497T3 (en) DERIVATIVES OF UREA, ITS PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9405111A (en) NEW DERIVATIVES OF (1-PHENYL-1-HETEROCICLIL) METHANOL AND (1-PHENYL-1-HETEROCICLIL-METHYLAMINE).
ATE295166T1 (en) ACTIVATORS OF POTASSIUM CHANNELS
AR013889A1 (en) NEW DERIVATIVES OF ACID 4- (1-PIPERAZINIL) -BENZOICO, PROCEDURE TO OBTAIN THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal